An optimal multi-period crossover design for an application in paediatric nephrology

Related Experiment Video

Updated: May 8, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

John N S Matthews1

  • 1School of Mathematics and Statistics, Newcastle University, Newcastle upon Tyne, NE1 7RU, U.K.

Statistics in Medicine
|September 13, 2013
PubMed

Insights

This study details an optimal 30-period crossover trial for comparing anticoagulants in pediatric hemodialysis patients. The design minimized patient variation and accommodated small sample sizes effectively.

Area of Science:

  • Clinical Trials
  • Pediatric Nephrology
  • Pharmacology

Background:

  • Crossover trials offer advantages like reduced inter-patient variability and multiple patient observations.
  • These benefits are crucial in studies with small sample sizes, such as pediatric hemodialysis.
  • Standard crossover designs often have limited periods and models unsuitable for specific research needs.

Purpose of the Study:

  • To derive and apply an optimal crossover trial design for comparing anticoagulants in pediatric hemodialysis.
  • To address the limitations of standard crossover trials in the context of pediatric hemodialysis clot prevention.
  • To investigate the efficacy of two anticoagulants in a pediatric population with a high frequency of treatment.

Main Methods:

  • Development of an optimal crossover trial with an extended 30-period duration.
  • Application of the trial design to a cohort of nine pediatric patients undergoing hemodialysis.
  • Comparison of two anticoagulant treatments within the established crossover framework.

Main Results:

  • Successfully implemented a 30-period crossover trial, maximizing patient data within a small cohort.
  • Facilitated the comparison of two anticoagulants, accounting for individual patient variations.
  • Encountered and addressed data distributions that deviated from initial study design expectations.

Conclusions:

  • An extended-period crossover trial design is feasible and beneficial for pediatric hemodialysis research.
  • This methodology effectively minimizes inter-patient variability in anticoagulant efficacy studies.
  • The trial provided valuable insights despite unexpected data distribution characteristics.

Keywords:
censored regressioncrossover designcrossover trialoptimal design

More Related Videos

Optimization of Renal Organoid and Organotypic Culture for Vascularization, Extended Development, and Improved Microscopy Imaging12:49

Optimization of Renal Organoid and Organotypic Culture for Vascularization, Extended Development, and Improved Microscopy Imaging

Published on: March 28, 2020

Related Concept Videos

Crossover Experiments01:16

Crossover Experiments

Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...